Mouse Modeling Dissecting Macrophage–Breast Cancer Communication Uncovered Roles of PYK2 in Macrophage Recruitment and Breast Tumorigenesis.

Autor: Müller, Anna‐Katharina¹ (AUTHOR), Köhler, Ulrike A.¹ (AUTHOR), Trzebanski, Sébastien² (AUTHOR), Vinik, Yaron¹ (AUTHOR), Raj, Harsha Mohan¹ (AUTHOR), Girault, Jean‐Antoine³ (AUTHOR), Ben‐Chetrit, Nir⁴ (AUTHOR), Maraver, Antonio⁵ (AUTHOR), Jung, Steffen² (AUTHOR), Lev, Sima¹ (AUTHOR) sima.lev@weizmann.ac.il

Publikováno v: Advanced Science. Mar2022, Vol. 9 Issue 9, p1-18. 18p.

CASQ2 alleviates lung cancer by inhibiting M2 tumor-associated macrophage polarization and JAK/STAT pathway.

Autor: Ding Y; Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Gannan Medical University, Ganzhou City, Jiangxi Province, China., Yuan X; Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Gannan Medical University, Ganzhou City, Jiangxi Province, China., Wang Y; Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Gannan Medical University, Ganzhou City, Jiangxi Province, China., Yan J; Department of Oncology, First Affiliated Hospital of Gannan Medical University, Ganzhou City, Jiangxi Province, China.

Publikováno v: Journal of biochemical and molecular toxicology [J Biochem Mol Toxicol] 2024 Aug; Vol. 38 (8), pp. e23801.

A single dose of intravenous combretastatin A4‐phosphate is reasonably well tolerated and significantly reduces tumour vascularization in canine spontaneous cancers.

Autor: Abma, E.^1,2 eline.abma@ugent.be, De Spiegelaere, W.³, Vanderperren, K.⁴, Stock, E.⁴, Van Brantegem, L.⁵, Cornelis, I.¹, Daminet, S.¹, Ni, Y.⁶, Vynck, M.⁷, Verstraete, G.⁸, Smets, P.¹, De Rooster, H.^1,2

Publikováno v: Veterinary & Comparative Oncology. Dec2018, Vol. 16 Issue 4, p467-477. 11p.

Molecular scale study on the interactions of biocompatible nanoparticles with macrophage membrane and blood proteins.

Autor: Khedri, Mohammad, Afsharchi, Fatemeh, Souderjani, Amirhosein Hasanpour, Rezvantalab, Sima, Didandeh, Mohsen, Maleki, Reza, Musaie, Kiyan, Santos, Hélder A., Shahbazi, Mohammad‐Ali

Publikováno v: Nano Select; Aug2022, Vol. 3 Issue 8, p1252-1263, 12p

A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer.

Autor: Garon, Edward B.^1,2 egaron@mednet.ucla.edu, Neidhart, Jeffrey D.³, Gabrail, Nashat Y.⁴, de Oliveira, Moacyr R.⁵, Balkissoon, Jai⁶, Kabbinavar, Fairooz^1,2

Publikováno v: OncoTargets & Therapy. Nov2016, Vol. 9, p7275-7283. 9p.